In Brief: Warner-Lambert's Procanbid
Executive Summary
Warner-Lambert's Procanbid: Procainamide extended-release 500 mg and 1,000 mg tablets for twice-daily treatment of life-threatening ventricular arrhythmia will be in pharmacies in March and available for patients by late April, following Jan. 31 approval. AWP will be $2.50-$4.50 per day depending on dose. NDA 20-545 for Procanbid was filed in December 1994...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth